The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice
Open accessAbstract
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear hormone receptor that promotes fatty acid β-oxidation (FAO) and oxidative phosphorylation (OXPHOS). We and others have recently shown that PPARα and its target genes are downregulated, and FAO and OXPHOS are impaired in autosomal dominant polycystic kidney disease (ADPKD). However, whether PPARα and FAO/OXPHOS are causally linked to ADPKD progression is not entirely clear. We report that expression of PPARα and FAO/OXPHOS genes is downregulated, and in vivo β-oxidation rate of 3 H-labeled triolein is reduced in Pkd1 RC/RC mice, a slowly progressing orthologous model of ADPKD that closely mimics the human ADPKD phenotype. To evaluate the effects of upregulating PPARα, we conducted a 5-mo, randomized, preclinical trial by treating Pkd1 RC/RC mice with fenofibrate, a clinically available PPARα agonist. Fenofibrate treatment resulted in increased expression of PPARα and FAO/OXPHOS genes, upregulation of peroxisomal and mitochondrial biogenesis markers, and higher β-oxidation rates in Pkd1 RC/RC kidneys. MRI-assessed total kidney volume and total cyst volume, kidney-weight-to-body-weight ratio, cyst index, and serum creatinine levels were significantly reduced in fenofibrate-treated compared with untreated littermate Pkd1 RC/RC mice. Moreover, fenofibrate treatment was associated with reduced kidney cyst proliferation and infiltration by inflammatory cells, including M2-like macrophages. Finally, fenofibrate treatment also reduced bile duct cyst number, cyst proliferation, and liver inflammation and fibrosis. In conclusion, our studies suggest that promoting PPARα activity to enhance mitochondrial metabolism may be a useful therapeutic strategy for ADPKD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, improved mitochondrial function -including enhanced oxidative phosphorylation and mitochondrial biogenesis- has been consistently associated with macrophage reprogramming and fibrosis resolution (28–31).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [30]
In the citing paper
“Pharmacological activation of PPARα increases restorative macrophage populations (30), and its upregulation, together with PPARγ, may depend on AMPK activation, linking transcriptional control with metabolic reprogramming (35).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [30]
Citations
Cites
Cancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452 · cited 1×
“To meet these needs, cyst epithelial cells appear to rewire their metabolism by activating alternative pathways of glycolysis and glutaminolysis (11, 27).”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,657
Kang, H. M., Ahn, S. H., Choi, P., Ko, Y.-A., Han, S. H., Chinga, F., Park, A. S. D., Tao, J., Sharma, K., Pullman, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3762 · Cited by 1,555
MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways
Chau, B. N., Xin, C., Hartner, J. C., Ren, S., Castaño, A. P., Linn, G. R., Li, J., Tran, P. T., Kaimal, V., Huang, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003205 · Cited by 611
PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection
Tran, M. T., Zsengellér, Z. K., Berg, A. H., Khankin, E. V., Bhasin, M., Kim, W., Clish, C. B., Stillman, I. E., Karumanchi, S. A., Rhee, E. P., et al. (2016) · Nature · doi:10.1038/nature17184 · Cited by 546
Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy
Rowe, I., Chiaravalli, M., Mannella, V., Ulisse, V., Quilici, G., Pema, M., Song, X. W., Xu, H., Mari, S., Qian, F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3092 · Cited by 503
Kusminski, C. M., Holland, W. L., Sun, K., Park, J., Spurgin, S. B., Lin, Y., Askew, G. R., Simcox, J., McClain, D. A., Li, C., et al. (2012) · Nature Medicine · doi:10.1038/nm.2899 · Cited by 474
Self-citationFunctional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity
Hopp, K., Ward, C. J., Hommerding, C. J., Nasr, S. H., Tuan, H.-F., Gainullin, V. G., Rossetti, S., Torres, V. E., & Harris, P. C. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64313 · Cited by 442
Bae, K. T., Zhu, F., Chapman, A. B., Torres, V. E., Grantham, J. J., Guay‐Woodford, L. M., Baumgarten, D. A., King, B. F., Wetzel, L. H., Kenney, P. J., et al. (2005) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00080605 · Cited by 311
Cited by
Sorted by citations
Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease
Mitrofanova, A. V., Merscher, S., & Fornoni, A. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00741-w · Cited by 382
Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease
Torres, J. A., Kruger, S. L., Broderick, C., Amarlkhagva, T., Agrawal, S., Dodam, J. R., Mrug, M. M., Lyons, L. A., & Weimbs, T. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.012 · Cited by 223
Lee, E. C. Y., Valencia, T., Allerson, C. R., Schairer, A., Flaten, A., Yheskel, M., Kersjes, K., Li, J., Gatto, S., Takhar, M. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11918-y · Cited by 193
Self-citationMetabolism and mitochondria in polycystic kidney disease research and therapy
Padovano, V., Podrini, C., Boletta, A., & Caplan, M. J. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0051-1 · Cited by 182
Defective Mitochondrial Fatty Acid Oxidation and Lipotoxicity in Kidney Diseases
Jang, H., Noh, M. R., Kim, J., & Padanilam, B. J. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00065 · Cited by 170
The multifaceted role of kidney tubule mitochondrial dysfunction in kidney disease development
Doke, T., & Suszták, K. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.03.012 · Cited by 164
Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease
Nowak, K. L., & Hopp, K. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13291019 · Cited by 128
Metabolic reprogramming and the role of mitochondria in polycystic kidney disease
Podrini, C., Cassina, L., & Boletta, A. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109495 · Cited by 124
Podrini, C., Rowe, I., Pagliarini, R., Costa, A. S. H., Chiaravalli, M., Meo, I. D., Kim, H., Distefano, G., Tiranti, V., Qian, F., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0200-x · Cited by 118
The pathobiology of polycystic kidney disease from a metabolic viewpoint
Menezes, L. F., & Germino, G. G. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0183-y · Cited by 96
The role of lipotoxicity in kidney disease: From molecular mechanisms to therapeutic prospects
Ren, L., Cui, H., Wang, Y., Ju, F., Cai, Y., Gang, X., & Wang, G. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114465 · Cited by 104
A methionine-Mettl3-N-methyladenosine axis promotes polycystic kidney disease
Ramalingam, H., Kashyap, S., Cobo-Stark, P., Flaten, A., Chang, C.-M., Hajarnis, S. S., Hein, K. Z., Lika, J., Warner, G. M., Espíndola‐Netto, J. M., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.024 · Cited by 94
Self-citationLeonhard, W. N., Song, X., Kanhai, A. A., Iliuta, I.-A., Božović, A., Steinberg, G. R., Peters, D. J. M., & Pei, Y. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.041 · Cited by 86
The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases
Gao, J., & Gu, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.832732 · Cited by 73
PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression
Lakhia, R., Ramalingam, H., Chang, C.-M., Cobo-Stark, P., Biggers, L. M., Flaten, A., Alvarez, J., Valencia, T., Wallace, D. P., Lee, E. C. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32543-2 · Cited by 75
Self-citationLipid homeostasis in diabetic kidney disease
Wang, Y., Liu, T., Wu, Y., Wang, L., Ding, S., Hou, B., Zhao, H., Liu, W., & Li, P. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.95216 · Cited by 75
Druggability of lipid metabolism modulation against renal fibrosis
Chen, Y., Chen, X., & Zhang, S. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00660-1 · Cited by 65
Arroyo, J., Escobar-Zarate, D., Wells, H. H., Constans, M., Thao, K., Smith, J. M., Sieben, C. J., Martell, M. R., Kline, T. L., Irazabal, M. V., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.01.028 · Cited by 58
Tubular Cell Glucose Metabolism Shift During Acute and Chronic Injuries
Faivre, A., Verissimo, T., Auwerx, H., Legouis, D., & de Seigneux, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.742072 · Cited by 64
Luo, Z., Li, M., Yang, Q., Zhang, Y., Liu, F., Gong, L., Han, L., & Wang, M. (2022) · Nutrients · doi:10.3390/nu14122530 · Cited by 55
Cassina, L., Chiaravalli, M., & Boletta, A. (2020) · The FASEB Journal · doi:10.1096/fj.201901739rr · Cited by 52
Functional interplay of lipid droplets and mitochondria
Enkler, L., & Spang, A. (2024) · FEBS Letters · doi:10.1002/1873-3468.14809 · Cited by 59
Repair of airway epithelia requires metabolic rewiring towards fatty acid oxidation
Crotta, S., Villa, M., Major, J., Finsterbusch, K., Llorian, M., Carmeliet, P., Buescher, J. M., & Wack, A. (2023) · Nature Communications · doi:10.1038/s41467-023-36352-z · Cited by 50
Xu, Z., Yang, S., Tan, Y., Zhang, Q., Wang, H., Tao, J., Liu, Q., Wang, Q., Feng, W., Li, Z., et al. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05379-9 · Cited by 64
Yheskel, M., Lakhia, R., Cobo-Stark, P., Flaten, A., & Patel, V. (2019) · Scientific Reports · doi:10.1038/s41598-019-38566-y · Cited by 49
Self-citationInsights Into the Molecular Mechanisms of Polycystic Kidney Diseases
Vasileva, V. Y., Sultanova, R. F., Sudarikova, A. V., & Ilatovskaya, D. V. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.693130 · Cited by 48
Impact of fenofibrate on NAFLD/NASH: A genetic perspective
Mahmoudi, A. A., Jamialahmadi, T., Johnston, T. P., & Sahebkar, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.007 · Cited by 46
Lin, P., & Duann, P. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.01050 · Cited by 45
Yang, M., Luo, S., Yang, J., Chen, W., He, L., Liu, D., Zhao, L., & Wang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1017387 · Cited by 46
Polycystic Liver Disease: Advances in Understanding and Treatment
Masyuk, T. V., Masyuk, A. I., & LaRusso, N. F. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-121247 · Cited by 40
Mu, Y.-W., Cheng, D., Zhang, C., Zhao, X., & Zeng, T. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.162187 · Cited by 39
Drug repurposing in autosomal dominant polycystic kidney disease
Zhou, J. X., & Torres, V. E. (2023) · Kidney International · doi:10.1016/j.kint.2023.02.010 · Cited by 40
Gluconeogenesis in the kidney: in health and in chronic kidney disease
Dalga, D., Verissimo, T., & de Seigneux, S. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad046 · Cited by 39
Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles
Malas, T. B., Leonhard, W. N., Bange, H., Granchi, Z., Hettne, K. M., van Westen, G. J. P., Price, L., Hoen, P. A. C. ’., & Peters, D. J. M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.046 · Cited by 40
Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease
Weimbs, T., Shillingford, J. M., Torres, J. A., Kruger, S. L., & Bourgeois, B. C. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy089 · Cited by 37
Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease
Hopp, K., Kleczko, E. K., Gitomer, B. Y., Chonchol, M., Klawitter, J., Christians, U., & Klawitter, J. (2022) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00262.2021 · Cited by 36
Harnessing metabolism of hepatic macrophages to aid liver regeneration
Liu, R., Scimeca, M., Sun, Q., Melino, G., Mauriello, A., Shao, C., Bernassola, F., Bove, P., Candi, E., Valentina, R., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06066-7 · Cited by 38
Song, X., Tsakiridis, E. E., Steinberg, G. R., & Pei, Y. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109704 · Cited by 36
Mi, Z., Song, Y., Cao, X., Lu, Y. H., Liu, Z., Zhu, X., Geng, M., Sun, Y., Lan, B., He, C., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0227-4 · Cited by 34
Liu, X., Du, H., Sun, Y., & Shao, L. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2072743 · Cited by 36
Reprogramming of Energy Metabolism in Kidney Disease
Singh, P. (2022) · The Nephron journals/Nephron journals · doi:10.1159/000526308 · Cited by 36
Immunometabolism changes in fibrosis: from mechanisms to therapeutic strategies
Feng, L., Chen, X., Huang, Y., Zhang, X., Zheng, S., & Xie, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1243675 · Cited by 35
Genetics, pathobiology and therapeutic opportunities of polycystic liver disease
Olaizola, P., Rodrigues, P. M., Caballero-Camino, F. J., Izquierdo‐Sánchez, L., Aspichueta, P., Bujanda, L., LaRusso, N. F., Drenth, J. P. H., Perugorria, M. J., & Bañales, J. M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00617-7 · Cited by 37
Modulation of polycystic kidney disease by non-coding RNAs
Ramalingam, H., Yheskel, M., & Patel, V. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109548 · Cited by 34
Self-citationSodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
Afşar, B., Afşar, R. E., Demiray, A., Altay, S., Korkmaz, H., Yıldız, A., Covic, A. C., Ortíz, A., & Kanbay, M. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac029 · Cited by 35
Role of ectopic olfactory receptors in glucose and lipid metabolism
Zhang, S., Li, L., & Li, H. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15666 · Cited by 32
Balakumar, P., Ramanathan, S., Mahadevan, N., Muhsinah, A. B., Alsayari, A., Venkateswaramurthy, N., & Dhanaraj, S. A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.025 · Cited by 30
Metabolic Reprogramming in Kidney Diseases: Evidence and Therapeutic Opportunities
Li, Y., Sha, Z., & Peng, H. (2021) · International Journal of Nephrology · doi:10.1155/2021/5497346 · Cited by 32
Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis
Mahmoudi, A. A., Butler, A. E., Majeed, M. A., Banach, M., & Sahebkar, A. (2022) · Nutrients · doi:10.3390/nu14071331 · Cited by 30
Cao, M., Zhao, X., Xia, F., Shi, M., Zhao, D., Li, L., & Jiang, H. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1623500 · Cited by 29
Woodley, K. T., Dillingh, L. S., Giotopoulos, G., Madrigal, P., Rattigan, K. M., Philippe, C., Dembitz, V., Magee, A. M. S., Asby, R., van de Lagemaat, L. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37652-0 · Cited by 32
Mechanisms of Cyst Development in Polycystic Kidney Disease
Qiu, J., Germino, G. G., & Menezes, L. F. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.03.001 · Cited by 28
Nguyen, D. T., Kleczko, E. K., Dwivedi, N., Monaghan, M. T., Gitomer, B. Y., Chonchol, M. B., Clambey, E. T., Nemenoff, R. A., Klawitter, J., & Hopp, K. (2022) · JCI Insight · doi:10.1172/jci.insight.154773 · Cited by 28
Zhang, Y.-H., Liu, B., Meng, Q., Zhang, D., Yang, H., Li, G., Wang, Y.-X., Liu, M., Liu, N., Yu, J., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107105 · Cited by 26
Zhang, L., Tian, M., Zhang, M., Li, C., Wang, X., Long, Y., Wang, Y., Hu, J., Chen, C., Chen, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202405325 · Cited by 25
ADPKD current management and ongoing trials
Testa, F., & Magistroni, R. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00679-y · Cited by 28
Enhancer and super-enhancer landscape in polycystic kidney disease
Lakhia, R., Mishra, A., Biggers, L. M., Malladi, V. S., Cobo-Stark, P., Hajarnis, S. S., & Patel, V. (2021) · Kidney International · doi:10.1016/j.kint.2022.08.039 · Cited by 23
Self-citationFan, C., Zhu, W., Chen, Y., Zhu, W., & Ding, J. (2025) · MedComm · doi:10.1002/mco2.70415 · Cited by 30
Kanhai, A. A., Bange, H., Verburg, L., Dijkstra, K. L., Price, L., Peters, D. J. M., & Leonhard, W. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-58382-z · Cited by 24
Metabolic Changes in Polycystic Kidney Disease as a Potential Target for Systemic Treatment
Haumann, S., Müller, R., & Liebau, M. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176093 · Cited by 24
Repurposing mitochondria-targeted therapeutics for kidney diseases
Thompson, A. D., Raj, P. V. S., Scholpa, N. E., & Schnellmann, R. G. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.020 · Cited by 21
Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease
Pickel, L., Iliuta, I.-A., Scholey, J. W., Pei, Y., & Sung, H. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab131 · Cited by 21
Song, X., Pickel, L., Sung, H., Scholey, J. W., & Pei, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137173 · Cited by 19
Quinn, G. Z., Dhillon, P., & Suszták, K. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2020.01.010 · Cited by 19
Metabolism-based approaches for autosomal dominant polycystic kidney disease
Bakaj, I., & Pocai, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1126055 · Cited by 18
Modeling Neoplastic Growth in Renal Cell Carcinoma and Polycystic Kidney Disease
Millet-Boureima, C., He, S., Le, T. B. U., & Gamberi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083918 · Cited by 19
Morito, K., Shimizu, R., Kitamura, N., Park, S., Kishino, S., Ogawa, J., Fukuta, T., Kogure, K., & Tanaka, T. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.07.010 · Cited by 17
Tian, H., Luo, J., Shi, H., Chen, X., Wu, J., Liang, Y., Li, C., & Loor, J. J. (2020) · Journal of Animal Science · doi:10.1093/jas/skaa062 · Cited by 17
MicroRNAs and Polycystic Kidney Disease
Li, D., & Sun, L. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.06.013 · Cited by 17
Perilipin 2 Impacts Acute Kidney Injury via Regulation of PPARα
Xu, S., Lee, E., Sun, Z., Wang, X., Ren, T., Zou, Z., Jin, J., Li, J., Zhang, J., Li, Y., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/9972704 · Cited by 16
Formica, C., Malas, T. B., Balog, J., Verburg, L., Hoen, P. A. C. ’., & Peters, D. J. M. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01852-3 · Cited by 15
Transmembrane protein 135 regulates lipid homeostasis through its role in peroxisomal DHA metabolism
Landowski, M., Bhute, V. J., Grindel, S. H., Haugstad, Z., Gyening, Y. K., Tytanic, M., Brush, R. S., Moyer, L. J., Nelson, D. W., Davis, C. R., et al. (2023) · Communications Biology · doi:10.1038/s42003-022-04404-7 · Cited by 15
Autosomal dominant polycystic kidney disease
Ong, A. C. M., Carriazo, S. M., Mingyao, B., Torrá, R., & Pei, Y. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00046-2 · Cited by 14
NPRA promotes fatty acid metabolism and proliferation of gastric cancer cells by binding to PPARα
Cao, T., Wang, S., Qian, L., Wu, C., Huang, T., Wang, Y., Li, Q., Wang, J., Xia, Y., Xu, L., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101734 · Cited by 14
Role of peroxisomes in the pathogenesis and therapy of renal fibrosis
Zhang, D., Zhang, Y.-H., Liu, B., Yang, H., Li, G., Zhou, H., & Wang, Y. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156173 · Cited by 14
Seliger, S. L., Watnick, T. J., Althouse, A. D., Perrone, R. D., Abebe, K. Z., Hallows, K. R., Miskulin, D. C., & Bae, K. T. (2020) · Kidney360 · doi:10.34067/kid.0004002020 · Cited by 14
Zhou, X., Xiong, H., Lu, Y., Geng, M., Lu, Y., Zhang, L., & Zhu, X. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.012 · Cited by 13
Torres, J. A., Holznecht, N. J., Asplund, D. A., Kroes, B. C., Amarlkhagva, T., Haeffner, M. M., Sharpe, E. H., Koestner, S., Strubl, S., Schimmel, M. F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110773 · Cited by 13
Pagliarini, R., & Podrini, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.740087 · Cited by 14
Neferine alleviates acute kidney injury by regulating the PPAR-α/NF-κB pathway
Xiong, Y., Zhong, J., Chen, W., Li, X., Liu, H. S., Li, Y., Xiong, W., & Li, H. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02504-8 · Cited by 12
PPARα Agonist WY-14643 Relieves Neuropathic Pain through SIRT1-Mediated Deacetylation of NF-κB
Wen, W., Wang, J., Zhang, B., & Wang, J. (2020) · PPAR Research · doi:10.1155/2020/6661642 · Cited by 12
Natural compounds regulating fatty acid oxidation in the treatment of diabetic kidney disease
Sun, J., Yin, C., Li, Z., Gao, X., Li, S., Gao, H., An, Y., Liu, P., & Na, L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1669557 · Cited by 11
Ortega-Lozano, A. J., Jiménez‐Uribe, A. P., Aranda‐Rivera, A. K., Gómez‐Caudillo, L., Ríos‐Castro, E., Tapia, E., Bellido, B., Aparicio‐Trejo, O. E., Sánchez‐Lozada, L. G., & Pedraza‐Chaverrí, J. (2022) · Metabolites · doi:10.3390/metabo12100936 · Cited by 11
Nakashima, M., Suga, N., Ikeda, Y., Yoshikawa, S., & Matsuda, S. (2024) · Biomolecules · doi:10.3390/biom14020207 · Cited by 11
Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression
Chen, J., Zhou, Q., Su, L., & Ni, L. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2506812 · Cited by 11
The role of PPARα in autosomal dominant polycystic kidney disease
Lakhia, R. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000615 · Cited by 11
Self-citationJamadar, A., Ward, C. J., Remadevi, V., Varghese, M. M., Pabla, N., Gumz, M. L., & Rao, R. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000528 · Cited by 10
Metabolic reprogramming in polycystic kidney disease and other renal ciliopathies
Clerici, S., & Boletta, A. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00239-x · Cited by 10
Gao, J., & Yu, X.-Y. (2025) · Biomedicines · doi:10.3390/biomedicines13071596 · Cited by 10
Iliuta, I.-A., Song, X., Pickel, L., Haghighi, A., Retnakaran, R. R., Scholey, J. W., Sung, H., Steinberg, G. R., & Pei, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.962933 · Cited by 14
Research progress on macrophages in cardiovascular diseases
Zhu, M., Zhou, H., Zhou, L., Yang, Y., & Chen, R. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03541-4 · Cited by 9
Fenofibrate differentially activates PPARα-mediated lipid metabolism in rat kidney and liver
Pannala, V. R., Balik-Meisner, M. R., Mav, D., Phadke, D. P., Scholl, E. H., Shah, R., Casey, W., Auerbach, S. S., & Wallqvist, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-20731-1 · Cited by 10
Disruption of polycystin-1 cleavage leads to cardiac metabolic rewiring in mice
Amaral, A. G., da Silva, C. C. C., Serna, J. D. C., Sampaio, K. H., de Freitas, J. A., Duarte‐Neto, A. N., Bloise, A. C., Cassina, L., Yoshinaga, M. Y., Chaves‐Filho, A. B., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166371 · Cited by 7
Wilk, E. J., Howton, T. C., Fisher, J. L., Oza, V. H., Brownlee, R. T., McPherson, K. C., Cleary, H. L., Yoder, B. K., George, J. F., Mrug, M. M., et al. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00664-z · Cited by 8
Cheng, T., Mariappan, A., Langner, E., Shim, K., Gopalakrishnan, J., & Mahjoub, M. R. (2024) · JCI Insight · doi:10.1172/jci.insight.172047 · Cited by 7
Activation of circulating monocytes by low-density lipoprotein—a risk factor for osteoarthritis?
Kruisbergen, N. N. L., van Gemert, Y., Blom, A. B., van den Bosch, M. H. J., & van Lent, P. L. E. M. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac359 · Cited by 6
Park, S.-J., Lee, Y.-S., Yoon, J. P., & Chung, S. W. (2025) · The American Journal of Sports Medicine · doi:10.1177/03635465251382858 · Cited by 5
Kędzierska-Kapuza, K., Łopuszyńska, I., Niewiński, G., Franek, E., & Szczuko, M. (2024) · Nutrients · doi:10.3390/nu16183216 · Cited by 5
Lakhia, R., Song, C., Biggers, L. M., Zumwalt, M., Alvarez, J., Somasundarum, A., Ramalingam, H., Cobo-Stark, P., & Patel, V. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkaf1538 · Cited by 4
Self-citationGaravaglia, C., Ossoli, A., & Gomaraschi, M. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02654-0 · Cited by 5
Metadata
- Authors
- Lakhia, R., Yheskel, M., Flaten, A., Quittner-Strom, E. B., Holland, W. L., & Patel, V.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Patel, Vishal
- ORCID
- Venue
- American Journal of Physiology-Renal Physiology
- Publisher
- American Physiological Society
- Published
- 2018-01-01
- Volume
- 314
- Issue
- 1
- Pages
- F122-F131
- ISSN
- 1522-1466 (ISSN-L)
- 1931-857X
- PMC
- PMC5866355
- OpenAlex
- W2754464449
- Cited by
- 140
- References
- 38
- Citations by year
- 2026: 19 · 2025: 19 · 2024: 21 · 2023: 15 · 2022: 20 · 2021: 15 · 2020: 17 · 2019: 11 · 2018: 3
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Physiology-Renal Physiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (DK102572)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Keywords
- PPARα, fenofibrate, fatty acid beta-oxidation, oxidative phosphorylation, autosomal dominant polycystic kidney disease, mitochondrial biogenesis, peroxisome biogenesis, renal cysts, bile duct cyst, liver fibrosis, M2 macrophages, liver inflammation, mitochondrial metabolism
- MeSH terms
- Animals, Cysts, Fatty Acids, Fatty Liver, Polycystic Kidney Diseases, Liver Diseases, Mice, Transgenic, Oxidation-Reduction, Transcription Factors, PPAR alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
